Novocure Q1 revenue $155M (+12% YoY), net loss $34.3M; CE Mark for Optune Lua NSCLC

NovoCure Ltd

2025-Q1 EPS reported -$0.31 revenue$154,994,000

Revenue $155M, +12% YoY; net loss $34.3M ($0.31 loss per share); adj. EBITDA -$5.0M; cash $929M.
Active patients 4,268; Optune Gio active patients +9% to 4,162; Optune Lua patients 106 (62 NSCLC, 44 MPM).
CE Mark approved for Optune Lua with immune checkpoint inhibitors or docetaxel in metastatic NSCLC after platinum progression.
Tariff risk: up to $11M if tariffs resume post-90-day pause; up to $8M if pause extended; monitoring mitigation.
PANOVA-3 Phase 3 pancreatic cancer results accepted as late-breaking abstract at ASCO 2025; milestones H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.